ストックスクリーナーアプリを入手
222.47
0.40%
0.88
アフターアワーズ：
222.03
-0.44
-0.20%
Abbvie Inc (ABBV) 最新ニュース
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie Stock in 2026: Skyrizi and Rinvoq Drive 12% Revenue Growth as Margins Begin to Inflect - TIKR.com
S&P upgrades AbbVie outlook on immunology drug growth By Investing.com - Investing.com Australia
S&P upgrades AbbVie outlook on immunology drug growth - Investing.com
AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 Trade Ideas — BCBA:ABBV.CI - TradingView
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - GlobeNewswire Inc.
AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73 - Yahoo Finance
AbbVie (ABBV) Receives a Hold from Citi - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV) - The Globe and Mail
AbbVie (ABBV) Rises Higher Than Market: Key Facts - Yahoo Finance
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
NYLIM VP Epoch U.S. Equity Yield Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients - Benzinga
AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy (NYSE:ABBV) - Seeking Alpha
AbbVie presents Phase III venetoclax data in first-line CLL - The Pharma Letter
AbbVie reports nine-year CLL14 trial data for Venclexta at EHA 2026 - grafa.com
6,889 Shares in AbbVie Inc. $ABBV Bought by Winning Points Advisors LLC - MarketBeat
Woodley Farra Manion Portfolio Management Inc. Has $5.30 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. - Yahoo Finance
Logan Capital Management Inc. Sells 8,592 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results - Investing News Network
AbbVie (ABBV) Reveals Promising Phase 3 Data on CLL Treatment - GuruFocus
AbbVie Inc. $ABBV Shares Sold by Sepio Capital LP - MarketBeat
Nuveen LLC Grows Stock Position in AbbVie Inc. $ABBV - MarketBeat
SmartHarvest Portfolios LLC Buys Shares of 9,927 AbbVie Inc. $ABBV - MarketBeat
AbbVie presents nine-year CLL14 trial results at EHA congress By Investing.com - Investing.com Canada
Leukemia patients go 7.6 years before next treatment in AbbVie trial - Stock Titan
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $275 - Moomoo
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
AbbVie Loses Colorado 340B Drug Pricing Law Challenge - Law360
AbbVie: Growth-Pharma Profile At A Value-Pharma Price (NYSE:ABBV) - Seeking Alpha
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225 - Yahoo Finance
Is AbbVie Inc. (ABBV) A Good Stock To Buy Now? - Insider Monkey
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026? - TradingView
Zions Bancorporation National Association UT Sells 12,395 Shares of AbbVie Inc. $ABBV - MarketBeat
M Holdings Securities Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie, Devon Energy And More On CNBC's 'Final Trades' - Benzinga
AbbVie Inc. $ABBV Shares Acquired by Wellspring Financial Advisors LLC - MarketBeat
Saturna Capital Corp Purchases 31,143 Shares of AbbVie Inc. $ABBV - MarketBeat
Smithbridge Asset Management Inc. DE Buys 18,364 Shares of AbbVie Inc. $ABBV - MarketBeat
Signet Private Wealth LLC Invests $1.20 Million in AbbVie Inc. $ABBV - MarketBeat
Townsquare Capital LLC Has $6.98 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Illinois Municipal Retirement Fund Lowers Position in AbbVie Inc. $ABBV - MarketBeat
Janney Montgomery Scott LLC Grows Position in AbbVie Inc. $ABBV - MarketBeat
Dorsey & Whitney Trust CO LLC Reduces Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
HUTNER CAPITAL MANAGEMENT INC's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc. stock (US00287Y1091): investors eye Skyrizi/Humira dynamics after recent data update - AD HOC NEWS
Final Trades: AbbVie, Devon Energy and the 2-Year and 10-Year Treasuries - CNBC
AbbVie Receives Complete Response Letter From FDA For TrenibotE Biologics License Application - marketscreener.com
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics - AbbVie News Center
AbbVie's migraine drug cleared for migraine attacks on NHS - pharmaphorum
AbbVie Inc. $ABBV Stock Position Lessened by Letko Brosseau & Associates Inc. - MarketBeat
Stonebrook Private Inc. Sells 8,844 Shares of AbbVie Inc. $ABBV - MarketBeat
9,254 Shares in AbbVie Inc. $ABBV Purchased by North Dallas Bank & Trust Co. - MarketBeat
Deutsche Bank AG Raises Position in AbbVie Inc. $ABBV - MarketBeat
BLI Banque de Luxembourg Investments Sells 5,100 Shares of AbbVie Inc. $ABBV - MarketBeat
Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law - Law360
NICE backs AbbVie’s Aquipta for acute migraine treatment - The Pharma Letter
AbbVie Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
AbbVie (ABBV) Is Proving the Post-Humira Story Is About Skyrizi, Rinvoq, and Portfolio Depth - AlphaStreet
ABBV: Growth driven by immunology, oncology, neuroscience, and obesity, with robust pipeline progress - TradingView
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM) - The Globe and Mail
AbbVie Inc. stock (US00287Y1091): FDA decision and pipeline catalysts keep focus on growth - AD HOC NEWS
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month? - The Globe and Mail
Inflammatory Bowel Disease Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly, Gilead - Barchart.com
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 - Investing News Network
0.42%
0.23%
大文字化:
|
ボリューム (24 時間):